A new trading day began on Friday, with Arcus Biosciences Inc (NYSE: RCUS) stock price down -6.47% from the previous day of trading, before settling in for the closing price of $8.5. RCUS’s price has ranged from $6.50 to $18.98 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -10.20%. Meanwhile, its annual earnings per share averaged -46.97%. With a float of $63.79 million, this company’s outstanding shares have now reached $105.90 million.
Let’s determine the extent of company efficiency that accounts for 627 employees. In terms of profitability, gross margin is 96.45%, operating margin of -309.22%, and the pretax margin is -277.3%.
Arcus Biosciences Inc (RCUS) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Arcus Biosciences Inc is 39.75%, while institutional ownership is 62.43%. The most recent insider transaction that took place on Feb 27 ’25, was worth 201,200. In this transaction Director of this company bought 20,000 shares at a rate of $10.06, taking the stock ownership to the 28,400 shares. Before that another transaction happened on Feb 27 ’25, when Company’s Chief Executive Officer bought 19,800 for $10.18, making the entire transaction worth $201,465. This insider now owns 2,554,160 shares in total.
Arcus Biosciences Inc (RCUS) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -46.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -6.14% during the next five years compared to -10.20% drop over the previous five years of trading.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
Here are Arcus Biosciences Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.19, a number that is poised to hit -1.13 in the next quarter and is forecasted to reach -4.49 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
Looking closely at Arcus Biosciences Inc (NYSE: RCUS), its last 5-days average volume was 1.4 million, which is a jump from its year-to-date volume of 1.1 million. As of the previous 9 days, the stock’s Stochastic %D was 15.84%.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 19.86%, which indicates a significant increase from 1.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 51.66% in the past 14 days, which was lower than the 71.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.76, while its 200-day Moving Average is $12.54. However, in the short run, Arcus Biosciences Inc’s stock first resistance to watch stands at $8.42. Second resistance stands at $8.90. The third major resistance level sits at $9.15. If the price goes on to break the first support level at $7.69, it is likely to go to the next support level at $7.44. Now, if the price goes above the second support level, the third support stands at $6.96.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
With a market capitalization of 841.79 million, the company has a total of 105,885K Shares Outstanding. Currently, annual sales are 258,000 K while annual income is -283,000 K. The company’s previous quarter sales were 28,000 K while its latest quarter income was -112,000 K.
